Paroxysmal familial ventricular fibrillation

Summary

Paroxysmal familial ventricular fibrillation (MONDO:0100234) is a disease with 5 cohort genes and 186 clinical trials. Top therapeutic interventions include ganirelix, cetrorelix, and estradiol valerate.

At a glance

• Prevalence: Unknown (Worldwide)
• Cohort genes: 5
• ClinVar variants: 5
• Clinical trials: 186

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	paroxysmal familial ventricular fibrillation
Mondo ID	MONDO:0100234
Orphanet	228140
UMLS	C0340493
MedGen	83310
GARD	0004227
Is cancer (heuristic)	no

Also known as: idiopathic ventricular fibrillation · idiopathic ventricular fibrillation, non Brugada type · IVF · paroxysmal familial ventricular fibrillation · paroxysmal familial ventricular fibrillation (disorder) · paroxysmal ventricular fibrillation · ventricular fibrillation, paroxysmal familial

Data availability: 5 ClinVar variants · 2 GenCC gene-disease records · 9 cell lines.

Disease family

An umbrella term covering 2 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › heart disorder › cardiac rhythm disease › ventricular fibrillation › paroxysmal familial ventricular fibrillation

Subtypes (2): ventricular fibrillation, paroxysmal familial, type 1, ventricular fibrillation, paroxysmal familial, 2

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

5 retrieved; paginated sample, class counts are floors:

2 conflicting classifications of pathogenicity, 2 uncertain significance, 1 pathogenic/likely pathogenic

ClinVar	Variant (HGVS)	Gene	Classification	Review
1009997	NM_001035.3(RYR2):c.12424G>A (p.Ala4142Thr)	LOC126806068	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
161209	NM_201596.3(CACNB2):c.380C>T (p.Ala127Val)	CACNB2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
43683	NM_001018005.2(TPM1):c.240+4430G>A	TPM1-AS	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
217831	NM_004415.4(DSP):c.7186T>A (p.Tyr2396Asn)	DSP	Uncertain significance	criteria provided, multiple submitters, no conflicts
217834	NM_170707.4(LMNA):c.80C>G (p.Thr27Ser)	LOC129931597	Uncertain significance	criteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 29 · Orphanet: 22 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
DPP6	Supportive	Autosomal dominant	paroxysmal familial ventricular fibrillation	6
SCN5A	Supportive	Autosomal dominant	paroxysmal familial ventricular fibrillation	23

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
SCN5A	Orphanet:101016	Romano-Ward syndrome
SCN5A	Orphanet:130	Brugada syndrome
SCN5A	Orphanet:1344	Isolated atrial standstill
SCN5A	Orphanet:154	Familial isolated dilated cardiomyopathy
SCN5A	Orphanet:166282	Hereditary sick sinus syndrome
SCN5A	Orphanet:228140	Idiopathic ventricular fibrillation
SCN5A	Orphanet:334	Hereditary atrial fibrillation
SCN5A	Orphanet:871	Hereditary progressive cardiac conduction defect
DPP6	Orphanet:228140	Idiopathic ventricular fibrillation
DPP6	Orphanet:2514	Autosomal dominant primary microcephaly
CACNB2	Orphanet:130	Brugada syndrome
DSP	Orphanet:154	Familial isolated dilated cardiomyopathy
DSP	Orphanet:158687	Lethal acantholytic erosive disorder
DSP	Orphanet:2032	Idiopathic pulmonary fibrosis
DSP	Orphanet:293165	Skin fragility-woolly hair-palmoplantar keratoderma syndrome
DSP	Orphanet:293888	Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant
DSP	Orphanet:293899	Inherited isolated arrhythmogenic ventricular dysplasia, biventricular variant
DSP	Orphanet:293910	Inherited isolated arrhythmogenic cardiomyopathy, dominant-right variant
DSP	Orphanet:369992	Severe dermatitis-multiple allergies-metabolic wasting syndrome
DSP	Orphanet:476096	Erythrokeratodermia-cardiomyopathy syndrome
DSP	Orphanet:50942	Striate palmoplantar keratoderma
DSP	Orphanet:65282	Carvajal syndrome

Cohort genes → proteins

5 cohort genes, 4 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	5

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
SCN5A	HGNC:10593	ENSG00000183873	Q14524	Sodium channel protein type 5 subunit alpha	gencc
DPP6	HGNC:3010	ENSG00000130226	P42658	A-type potassium channel modulatory protein DPP6	gencc
CACNB2	HGNC:1402	ENSG00000165995	Q08289	Voltage-dependent L-type calcium channel subunit beta-2	clinvar
DSP	HGNC:3052	ENSG00000096696	P15924	Desmoplakin	clinvar
TPM1-AS	HGNC:53635	ENSG00000259498		TPM1 antisense RNA	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
SCN5A	Sodium channel protein type 5 subunit alpha	Pore-forming subunit of Nav1.5, a voltage-gated sodium (Nav) channel that directly mediates the depolarizing phase of action potentials in excitable membranes.
DPP6	A-type potassium channel modulatory protein DPP6	Promotes cell surface expression of the potassium channel KCND2.
CACNB2	Voltage-dependent L-type calcium channel subunit beta-2	Beta subunit of voltage-dependent calcium channels which contributes to the function of the calcium channel by increasing peak calcium current.
DSP	Desmoplakin	A component of desmosome cell-cell junctions which are required for positive regulation of cellular adhesion.

Protein-family classification

Druggable: 2 · Difficult: 2 · Unknown: 1 · Druggable fraction: 0.4

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Ion channel	1	22.3×	0.088
Scaffold/PPI	2	6.9×	0.088
Protease	1	7.3×	0.172
Other/Unknown	1	0.4×	0.983

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
SCN5A	Ion channel	yes		Na_channel_asu, Ion_trans_dom, Na_channel_a5su
DPP6	Protease	yes		Peptidase_S9_cat, Peptidase_S9B_N, AB_hydrolase_fold
CACNB2	Scaffold/PPI	no		VDCC_L_bsu, SH3_domain, VDCC_L_b2su
DSP	Scaffold/PPI	no		Plectin_repeat, SH3_domain, Spectrin/alpha-actinin
TPM1-AS	Other/Unknown	no

Expression context

Cohort genes with no expression data: 0.

4 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	5
unknown	0

Top tissues across cohort

Tissue	Cohort genes
apex of heart	2
cardiac ventricle	1
heart left ventricle	1
Brodmann (1909) area 23	1
endothelial cell	1
middle temporal gyrus	1
adrenal tissue	1
buccal mucosa cell	1
mucosa of stomach	1
hair follicle	1
skin of hip	1
upper leg skin	1
colonic epithelium	1
sural nerve	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
SCN5A	161	broad	yes	apex of heart, heart left ventricle, cardiac ventricle
DPP6	221	broad	marker	middle temporal gyrus, Brodmann (1909) area 23, endothelial cell
CACNB2	237	broad	marker	adrenal tissue, mucosa of stomach, buccal mucosa cell
DSP	253	ubiquitous	marker	skin of hip, upper leg skin, hair follicle
TPM1-AS	130	tissue_specific	marker	colonic epithelium, sural nerve, apex of heart

Protein interactions among cohort

Intra-cohort edges: 2.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
DSP	2,897
DPP6	2,224
SCN5A	2,090
CACNB2	1,425
TPM1-AS	0

Intra-cohort edges

A	B	Sources
CACNB2	SCN5A	string_interaction
DPP6	SCN5A	string_interaction

Structural data

PDB: 4 · AlphaFold-only: 0 · No structure: 1

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
SCN5A	Q14524	16
DPP6	P42658	8
DSP	P15924	4
CACNB2	Q08289	3

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 30. Enrichment computed across 5 evidence-associated genes (3 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Phase 0 - rapid depolarisation	2	230.7×	7e-04	SCN5A, CACNB2
Cardiac conduction	2	72.5×	0.004	SCN5A, CACNB2
Muscle contraction	2	51.4×	0.005	SCN5A, CACNB2
Axon guidance	2	30.1×	0.010	SCN5A, CACNB2
Nervous system development	2	28.6×	0.010	SCN5A, CACNB2
Apoptotic cleavage of cell adhesion proteins	1	346.1×	0.013	DSP
Presynaptic depolarization and calcium channel opening	1	317.2×	0.013	CACNB2
Phase 2 - plateau phase	1	253.8×	0.015	CACNB2
Mechanical load activates signaling by PIEZO1 and integrins in osteocytes	1	223.9×	0.015	CACNB2
Adrenaline,noradrenaline inhibits insulin secretion	1	131.3×	0.021	CACNB2
Interaction between L1 and Ankyrins	1	122.8×	0.021	SCN5A
Sensory processing of sound	1	102.9×	0.021	CACNB2
NCAM signaling for neurite out-growth	1	90.6×	0.021	CACNB2
RND1 GTPase cycle	1	88.5×	0.021	DSP
RND3 GTPase cycle	1	86.5×	0.021	DSP
Cellular responses to mechanical stimuli	1	86.5×	0.021	CACNB2
NCAM1 interactions	1	82.8×	0.021	CACNB2
Regulation of insulin secretion	1	73.2×	0.022	CACNB2
Developmental Biology	2	9.6×	0.022	SCN5A, CACNB2
Integration of energy metabolism	1	58.6×	0.025	CACNB2
Sensory processing of sound by inner hair cells of the cochlea	1	54.4×	0.026	CACNB2
L1CAM interactions	1	40.1×	0.034	SCN5A
Sensory Perception	1	31.7×	0.041	CACNB2
Formation of the cornified envelope	1	29.3×	0.042	DSP
Transmission across Chemical Synapses	1	25.4×	0.047	CACNB2
Keratinization	1	18.6×	0.061	DSP
Neuronal System	1	14.8×	0.074	CACNB2
Cellular responses to stimuli	1	10.5×	0.099	CACNB2
Neutrophil degranulation	1	7.7×	0.129	DSP
Metabolism	1	3.9×	0.237	CACNB2

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 4 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
membrane depolarization during atrial cardiac muscle cell action potential	2	2808.7×	4e-06	SCN5A, CACNB2
regulation of heart rate by cardiac conduction	3	280.9×	4e-06	SCN5A, CACNB2, DSP
membrane depolarization during AV node cell action potential	2	1685.2×	9e-06	SCN5A, CACNB2
bundle of His cell action potential	1	2106.5×	0.005	SCN5A
AV node cell to bundle of His cell communication	1	2106.5×	0.005	SCN5A
positive regulation of calcium ion transmembrane transport via high voltage-gated calcium channel	1	2106.5×	0.005	CACNB2
protein localization to plasma membrane	2	54.4×	0.005	CACNB2, DPP6
membrane depolarization during Purkinje myocyte cell action potential	1	1404.3×	0.005	SCN5A
membrane depolarization during bundle of His cell action potential	1	1404.3×	0.005	SCN5A
AV node cell action potential	1	1053.2×	0.006	SCN5A
membrane depolarization during SA node cell action potential	1	842.6×	0.006	SCN5A
regulation of ventricular cardiac muscle cell membrane depolarization	1	702.2×	0.006	SCN5A
SA node cell action potential	1	702.2×	0.006	SCN5A
ventricular compact myocardium morphogenesis	1	601.9×	0.006	DSP
cardiac ventricle development	1	601.9×	0.006	SCN5A
response to denervation involved in regulation of muscle adaptation	1	601.9×	0.006	SCN5A
positive regulation of muscle contraction	1	601.9×	0.006	CACNB2
regulation of atrial cardiac muscle cell membrane repolarization	1	601.9×	0.006	SCN5A
bundle of His cell-Purkinje myocyte adhesion involved in cell communication	1	601.9×	0.006	DSP
desmosome organization	1	526.6×	0.006	DSP
brainstem development	1	526.6×	0.006	SCN5A
positive regulation of action potential	1	526.6×	0.006	SCN5A
regulation of atrial cardiac muscle cell membrane depolarization	1	468.1×	0.006	SCN5A
protein localization to cell-cell junction	1	468.1×	0.006	DSP
membrane depolarization during action potential	1	421.3×	0.006	SCN5A
atrial cardiac muscle cell action potential	1	421.3×	0.006	SCN5A
peptide cross-linking	1	351.1×	0.006	DSP
membrane depolarization during cardiac muscle cell action potential	1	351.1×	0.006	SCN5A
regulation of ventricular cardiac muscle cell action potential	1	351.1×	0.006	DSP
epithelial cell-cell adhesion	1	300.9×	0.007	DSP

Therapeutics

Drug target analysis

Approved (phase 4): 2 · Phase ≥3: 2 · Phased (≥1): 2 · Undrugged: 3

Druggability breadth: 3 of 5 evidence-associated genes (60%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
SCN5A	BEPRIDIL
CACNB2	NIMODIPINE

Top cohort targets by molecule count

Symbol	Molecules	Max phase
SCN5A	108	4
CACNB2	2	4
DPP6	0	0
DSP	0	0
TPM1-AS	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
BEPRIDIL	4	SCN5A
CANDESARTAN CILEXETIL	4	SCN5A
TELMISARTAN	4	SCN5A
CARBAMAZEPINE	4	SCN5A
DIBUCAINE	4	SCN5A
IMIPRAMINE	4	SCN5A
DROPERIDOL	4	SCN5A
PONATINIB	4	SCN5A
DULOXETINE	4	SCN5A
PALONOSETRON	4	SCN5A
VILANTEROL	4	SCN5A
MEXILETINE HYDROCHLORIDE	4	SCN5A
UNOPROSTONE ISOPROPYL	4	SCN5A
LURASIDONE	4	SCN5A
LETERMOVIR	4	SCN5A
SERTINDOLE	4	SCN5A
FEDRATINIB	4	SCN5A
QUINIDINE	4	SCN5A
DARUNAVIR	4	SCN5A
DARIFENACIN	4	SCN5A
BENZONATATE	4	SCN5A
TOLTERODINE	4	SCN5A
RANOLAZINE	4	SCN5A
PIMOZIDE	4	SCN5A
NIMODIPINE	4	CACNB2, SCN5A
FELODIPINE	4	SCN5A
NICARDIPINE	4	SCN5A
AMLODIPINE	4	SCN5A
PHENYTOIN	4	SCN5A
PALIPERIDONE	4	SCN5A

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
SCN5A	594	Binding:380, Functional:98, ADMET:72, Toxicity:43, Unclassified:1
CACNB2	22	Binding:20, ADMET:1, Toxicity:1
DSP	2	Binding:2

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
SCN5A	594

Pharmacogenomics

Cohort genes with a PharmGKB record: 4; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
BEPRIDIL	4	SCN5A
CANDESARTAN CILEXETIL	4	SCN5A
TELMISARTAN	4	SCN5A
CARBAMAZEPINE	4	SCN5A
DIBUCAINE	4	SCN5A
IMIPRAMINE	4	SCN5A
DROPERIDOL	4	SCN5A
PONATINIB	4	SCN5A
DULOXETINE	4	SCN5A
PALONOSETRON	4	SCN5A
VILANTEROL	4	SCN5A
MEXILETINE HYDROCHLORIDE	4	SCN5A
UNOPROSTONE ISOPROPYL	4	SCN5A
LURASIDONE	4	SCN5A
LETERMOVIR	4	SCN5A
SERTINDOLE	4	SCN5A
FEDRATINIB	4	SCN5A
QUINIDINE	4	SCN5A
DARUNAVIR	4	SCN5A
DARIFENACIN	4	SCN5A
BENZONATATE	4	SCN5A
TOLTERODINE	4	SCN5A
RANOLAZINE	4	SCN5A
PIMOZIDE	4	SCN5A
NIMODIPINE	4	CACNB2, SCN5A
FELODIPINE	4	SCN5A
NICARDIPINE	4	SCN5A
AMLODIPINE	4	SCN5A
PHENYTOIN	4	SCN5A
PALIPERIDONE	4	SCN5A

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	2	SCN5A, CACNB2
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	1	DPP6
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	2	DSP, TPM1-AS

Undrugged target profiles

3 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
DPP6	0	SCN5A
DSP	2	—
TPM1-AS	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 186.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	154
PHASE4	15
PHASE3	6
PHASE2	5
PHASE2/PHASE3	3
PHASE1	2
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04487925	PHASE4	RECRUITING	Controlled Ovarian Stimulation Versus Modified Natural Cycles in Poor Responders
NCT06396390	PHASE4	NOT_YET_RECRUITING	Comparison of Progestin Primed Ovarian Stimulation (PPOS) vs.GnRH Antagonist Methods on IVF Outcomes
NCT07405229	PHASE4	RECRUITING	MEdical Treatment in Idiopathic Ventricular Fibrillation Patients
NCT07499804	PHASE4	RECRUITING	Effect of Tadalafil on Endometrial Thickness and Frozen Embryo Transfer Outcomes
NCT02201914	PHASE4	UNKNOWN	Clomiphene Citrate Plus Gonadotropins and GnRH Antagonist Versus Flexible GnRH Antagonist Protocol Versus Microdose GnRH Agonist Protocol in Poor Responders Undergoing IVF
NCT02651285	PHASE4	UNKNOWN	Use of G-CSF Supplemented IVF Medium in Patients Undergoing IVF
NCT04002635	PHASE4	WITHDRAWN	Letrozole for Frozen Embryo Transfer (FET) in Patients With Polycystic Ovary Syndrome (PCOS)
NCT04385342	PHASE4	UNKNOWN	FSH Followed by HMG vs FSH Plus HMG in IVF
NCT04654741	PHASE4	UNKNOWN	The Rate of Embryo Euploidy in Progestin-primed Ovarian Stimulation Cycles
NCT04728659	PHASE4	UNKNOWN	Desogestrel Versus GnRH Antagonist in IVF/ICSI
NCT04993924	PHASE4	UNKNOWN	GnRH Antagonist Pre-treatment in the Early Follicular Phase for Resolution of a Baseline Functional Ovarian Cyst
NCT05071339	PHASE4	UNKNOWN	GnRH Antagonist Pre-treatment for the Prevention of Asynchronous Follicular Growth
NCT05321511	PHASE4	UNKNOWN	Comparison of Triggers in Double Ovarian Stimulation (DuoStim).
NCT05954962	PHASE4	COMPLETED	Efficacy of Micronized Natural Progesterone vs GnRH Antagonist in the Prevention of LH Peak During Ovarian Stimulation.
NCT06181305	PHASE4	UNKNOWN	Endometrial Preparation in Frozen Embryo Transfer Cycles
NCT06405204	PHASE3	NOT_YET_RECRUITING	of Myo-inositol, Melatonin and Co-enzyme q10 on Ovarian Reserve
NCT07499817	PHASE3	RECRUITING	Effect of Pentoxyfilline on Endometrial Thickness and Frozen Embryo Transfer Outcomes
NCT04414761	PHASE3	COMPLETED	Live Birth Rate Between PPOS and GnRH Antagonist Protocol in Patients With Anticipated High Ovarian Response
NCT04806919	PHASE3	COMPLETED	Luteal Support in Artificial Vitrified/Warmed Cycles With Low Progesterone
NCT05951400	PHASE2/PHASE3	COMPLETED	Progesterone Primed Protocol Versus GnRH Antagonist in With PCO Undergoing ICSI
NCT05951413	PHASE2/PHASE3	UNKNOWN	The Effect of Sildenafil Citrate on Frozen Embryo Transfer Cycles
NCT05971667	PHASE2/PHASE3	UNKNOWN	Effect of Tadalafil, Sildenafil and Pentoxyfylline on Frozen Embryo Transfer Outcomes
NCT05972902	PHASE3	UNKNOWN	Dydrogesterone, Cetrorelix Acetate and Triptorelin in Intra Cytoplasmic Sperm Injection Outcomes
NCT06048666	PHASE3	UNKNOWN	Platelet Rich Plasma on Ovarian Reserve Parameters and Intra Cytoplasmic Sperm Injection Outcomes in Patients With Diminished Ovarian Reserve
NCT06555575	PHASE2	RECRUITING	Ubiquinone vs. Ubiquinol Supplementation
NCT06997900	PHASE2	RECRUITING	Menopur And Rekovelle Combination Study Version 2.0
NCT02677259	PHASE2	UNKNOWN	Luteal Phase Estradiol Support for In Vitro Fertilization/Intracytoplasmic Sperm Injection Cycles
NCT04524026	PHASE2	COMPLETED	RIOTC: Reducing the Impact of Ovarian Stimulation. Novel Approaches to Luteal Support in IVF-Study 2
NCT04778358	PHASE2	COMPLETED	Higher Dose of Rekovelle in Oocyte Donors
NCT04175990	PHASE1	COMPLETED	IVF Outcome Following Progestogen Ovarian Stimulation
NCT04283435	PHASE1	UNKNOWN	Endometrial Effects of Sildenafil in Frozen-Thawed Cycles in Women With Thin Endometrium
NCT06870266	EARLY_PHASE1	NOT_YET_RECRUITING	Comparison of Pregnancy Rates in Modified Natural Frozen Embryo Transfer (FET) Cycle After Luteal Support with GnRH Agonist Versus Progesterone
NCT04371783	Not specified	ACTIVE_NOT_RECRUITING	A Randomized Trial Comparing the Live Birth Rate of Immediate Versus Delayed FET Following a Freeze-all Strategy
NCT04381299	Not specified	ACTIVE_NOT_RECRUITING	Will Autologous Platelet Rich Plasma Able To Restore Ovarian Function?
NCT04390308	Not specified	RECRUITING	Is There A Role For Mechanical Stimulation In Ovarian Follicular Activation?
NCT04477863	Not specified	RECRUITING	Follow-up With Preimplantation Genetic Testing Patients
NCT04619524	Not specified	RECRUITING	Biomarkers of Endometrial Receptivity
NCT04748874	Not specified	ACTIVE_NOT_RECRUITING	Immediate Versus Postponed Single Blastocyst Transfer in mNC-FET
NCT04751084	Not specified	ACTIVE_NOT_RECRUITING	Buscopan in Patients Undergoing IVF/Intracytoplasmic Sperm Injection Treatment
NCT05017740	Not specified	ACTIVE_NOT_RECRUITING	PICSI RCT in Couples With a Previous Poor Fertilisation Cycle in IVF

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
GANIRELIX	4	6
CETRORELIX	4	5
ESTRADIOL VALERATE	4	4
CLOMIPHENE	4	3
DYDROGESTERONE	4	3
GONADORELIN ACETATE	4	3
DIENOGEST	4	2
FOLLITROPIN DELTA	4	2
LETROZOLE	4	2
PENTOXIFYLLINE	4	2
PROGESTERONE	4	2
TADALAFIL	4	2
TRIPTORELIN	4	2
DESOGESTREL	4	1
FOLIC ACID	4	1
FOLLITROPIN	4	1
FOLLITROPIN ALFA	4	1
GONADOTROPIN, CHORIONIC	4	1
MEDROXYPROGESTERONE ACETATE	4	1
MENOTROPINS	4	1
SCOPOLAMINE	4	1
ENCLOMIPHENE CITRATE	3	2
BUTYLSCOPOLAMINE BROMIDE	3	1
UBIDECARENONE	3	1
CHEMBL2370644	0	3
CHEMBL139521	0	2
CHEMBL177542	0	2
CHEMBL4244897	0	2
CHEMBL4792718	0	2
CHEMBL5439651	0	2